British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.
The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential ...
Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.
Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director ...
French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial.
Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European ...
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...
Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell ...
French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, ...
Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and ...
Undecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene ...
AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results